EMDA®+MMC to plug BCG shortage
BAUS, EAU and NICE have suggested that hospitals switch to our EMDA®+Mitomycin-C treatment due to the worldwide shortage of BCG.
BAUS, EAU and NICE have suggested that hospitals switch to our EMDA®+Mitomycin-C treatment due to the worldwide shortage of BCG.
We are counting down to BAUS 2019 in Glasgow next week.
Physion has appointed JS Consulting as their strategic advisor for the GCC & Middle East regions.
NICE has called for EMDA® to be used in research programmes as a treatment for bladder cancer.